MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $11,460.00 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of MaxCyte stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $3.82, for a total transaction of $11,460.00. Following the transaction, the director now directly owns 141,950 shares in the company, valued at $542,249. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Monday, August 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.28, for a total transaction of $12,840.00.
• On Friday, July 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.75, for a total transaction of $14,250.00.

MaxCyte Stock Performance

Shares of MXCT stock opened at $3.70 on Wednesday. MaxCyte, Inc. has a one year low of $2.45 and a one year high of $5.55. The firm’s 50 day moving average price is $4.17 and its 200-day moving average price is $4.26. The firm has a market cap of $387.85 million, a P/E ratio of -10.57 and a beta of 1.40.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The business had revenue of $10.43 million during the quarter, compared to analyst estimates of $8.20 million. During the same period last year, the business posted ($0.10) earnings per share. As a group, research analysts predict that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of MaxCyte during the first quarter worth $28,000. PNC Financial Services Group Inc. purchased a new position in shares of MaxCyte during the fourth quarter worth $29,000. China Universal Asset Management Co. Ltd. boosted its position in shares of MaxCyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock worth $83,000 after buying an additional 7,898 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of MaxCyte by 20.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after buying an additional 4,320 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of MaxCyte by 22.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after buying an additional 5,927 shares during the period. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.